Comparative efficacy of indacaterol 150 μg and 300 μg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease - A network meta-analysis

International Journal of COPD

Volumn 6, Issue 1, 2011, Pages 329-344

  Cope, Shannon ^a   Capkun Niggli, Gorana ^b   Gale, Rupert ^c   Jardim, José R ^d   Jansen, Jeroen P ^a  

^a MAPI VALUES   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

^d FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Copd; Indacaterol; Network meta analysis

Indexed keywords

BUDESONIDE PLUS FORMOTEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL; INDACATEROL; PLACEBO; SALMETEROL; TIOTROPIUM BROMIDE; 5 (2 (5,6 DIETHYLINDAN 2 YLAMINO) 1 HYDROXYETHYL) 8 HYDROXY 1H QUINOLIN 2 ONE; 5-(2-(5,6-DIETHYLINDAN-2-YLAMINO)-1-HYDROXYETHYL)-8-HYDROXY-1H-QUINOLIN-2-ONE; ANDROSTANE DERIVATIVE; BRONCHODILATING AGENT; BUDESONIDE; DRUG DERIVATIVE; ETHANOLAMINE DERIVATIVE; FLUTICASONE, SALMETEROL DRUG COMBINATION; FORMOTEROL; INDAN DERIVATIVE; QUINOLONE DERIVATIVE; SALBUTAMOL;

ADULT; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; META ANALYSIS; MONOTHERAPY; MULTICENTER STUDY (TOPIC); QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT PARAMETERS; REVIEW; SAINT GEORGE RESPIRATORY QUESTIONNAIRE; SCORING SYSTEM; TRANSITION DYSPNEA INDEX; TREATMENT OUTCOME; COMPARATIVE STUDY; DRUG COMBINATION;

ALBUTEROL; ANDROSTADIENES; BRONCHODILATOR AGENTS; BUDESONIDE; DRUG COMBINATIONS; ETHANOLAMINES; HUMANS; INDANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 80052694180     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S18759     Document Type: Review

References (30)

1. GOLD (Global Initiative for Chronic Obstructive Lung Disease). Global strategy for the diagnosis, management, and prevention of COPD. 2010. http://www.goldcopd.com/Guidelineitem.asp?l1=2&l2=1&intId=989. Accessed February 1, 2010.
2. Katz PM, Pegoraro V. L'utilizzo dei corticosteroidi nei pazienti con la broncopneumopatia cronica ostruttiva: aspetti epidemiologici ed economici. Farmeconomia e percorsi terapeutici. 2009;10(4): 139-148.
3. European Medicines Agency. Onbrez Breezhaler indacaterol. Doc.Ref.: EMA/625202/2009. 2010. http://www.ema.europa.eu/docs/en_GB/ document_library/EPAR_-_Summary_for_the_public/human/001114/ WC500053733.pdf. Accessed February 1, 2010.
4. Dahl R, Chung K F, Buhl R, et al. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010;65(6):473-479.
5. Donohue JF, Fogarty C, Lotvall J, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010;182(2):155-162.
6. Feldman G, Siler T, Prasad N, et al. Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med. 2010;10(11):1-9.
7. Kornmann O, Dahl R, Centanni S, et al. Once-daily indacaterol vs twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J. 2011;37:273-279.
8. Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ. 2005;331(7521):897-900.
9. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004;23(20):3105-3124.
10. Jansen J, Crawford B, Bergman G, Stam W. Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. Value Health. 2008;11(5):964-966.
11. Dempster A P. The direct use of likelihood for significance testing. Stat Comput. 1997;7:247-252.
12. Cooper NJ, Sutton AJ, Morris D, Ades AE, Welton NJ. Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: application to stroke prevention treatments in individuals with non-rheumatic atrial fbrillation. Stat Med. 2009;28: 1861-1881.
13. Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS - a Bayesian modeling framework: concepts, structure, and extensibility. Stat Comput. 2000;10:325-337.
14. Barnes N, Qiu Y, Pavord I, Parker D, Davis P, Zhu J, et al. Antiinfammatory effects of salmeterol/futicasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med. 2006;173(7):736-743.
15. Calverley P, Pauwels R, Vestbo Jr, et al. Combined salmeterol and futicasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003;361(9356):449-456.
16. Calverley P, Anderson J, Celli B, et al. Salmeterol and futicasone pro-pionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775-789.
17. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J. 2003;22(6):912-919.
18. Hanania N, Darken P, Horstman D, et al. The efficacy and safety of futica-sone propionate (250 mug)/salmeterol (50 mug) combined in the Diskus inhaler for the treatment of COPD. Chest. 2003;124(3):834-843.
19. Mahler D, Wire P, Horstman D, et al. Effectiveness of futicasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;166(8):1084-1091.
20. Rennard SI, Tashkin D, McElhattan J, et al. Efficacy and tolerability of budesonide/formoterol in one hydrofuoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs. 2009; 69(5):549-565.
21. Tashkin D P, Rennard SI, Martin P, et al. Efficacy and safety of budes-onide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs. 2008;68(14): 1975-2000.
22. Zheng J, Yang L, Wu Y, et al. The efficacy and safety of combination salmeterol (50 mug)/futicasone propionate (500 mug) inhalation twice daily via accuhaler in Chinese patients with COPD. Chest. 2007;132(6):1756-1763.
23. Iqbal A, Lean H, Lawrence D, Higgins M. Full Clinical Study Report for study number CQAB149B2335S: A 26-week treatment, multi center, randomized, double-blind, double dummy, placebo-controlled, adaptive, seamless, parallel-group study to assess the efficacy, safety and toler-ability of two doses of indacaterol (selected from 75, 150, 300 and 600 μg o.d.) in patients with chronic obstructive pulmonary disease using blinded formoterol (12 μg b.i.d) and open label tiotropium (18 μg o.d.) as active Controls. Data on fle: 2008.
24. Luthra A, Kramer B, Swales J, Henley M, Lassen C. Full Clinical Study Report for study number CQAB149B2336: A 26-week treatment, multi center, randomized, double blind, double dummy, placebo controlled, parallel group study to assess the efficacy and safety of indacaterol (150 μg o.d.) in patients with chronic obstructive pulmonary disease, using salmeterol (50 μg b.i.d.) as an active control. Data on fle: 2009.
25. Hosoe M, Okino N, Maruyama Y, et al. Full Clinical Study Report for study number CQAB149B1302: A 12-week treatment, multi-center, randomized, double blind, placebo-controlled, parallel group study to assess the efficacy, safety and tolerability of Indacaterol (150 and 300 ìg o.d.) in patients with chronic obstructive pulmonary disease (COPD). Data on fle: 2010.
26. Firth R, Henley M, Kramer B, Lassen C, Yang W, Owen R. Full Clinical Study Report for study number QAB149B2333: A phase III, 26-week multi-center randomized double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of indacaterol (150 and 300 ìg o.d.) in patients with chronic obstructive pulmonary disease. Data on fle: 2010.
27. Jack D, Bleasdale P, Berhane I, Higgins M. Full Clinical Study Report for study number CQAB149B2334: A 52-week treatment, multi center, randomized, double-blind, double dummy, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of indacaterol (300 and 600 μg o.d.) in patients with chronic obstructive pulmonary disease, using formoterol (12 μg b.i.d.) as an active control. Data on fle: 2008.
28. Prasad N, Piggott S, Higgins M, Yu T. Full Clinical Study Report for study number CQAB149B2346: A 12-week treatment, multi-center, randomized, doubleblind, placebo-controlled, parallel-group study to assess the efficacy and safety of indacaterol (150 μg o.d.) in patients with chronic obstructive pulmonary disease. Data on fle: 2008.
29. Jones P W. St. George's Respiratory Questionnaire: MCID. COPD. 2005;2(1):75-79.
30. Witek TJ Jr, Mahler DA. Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J. 2003;21(2):267-272.